ArticleBiology of the cell2025
Direct Profiling of Extracellular Vesicle Surface Markers in Plasma: A Proof-of-Concept Study.
Article in Biology of the cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct Profiling of Extracellular Vesicle Surface Markers in Plasma: A Proof-of-Concept Study.Biology of the cell · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
During the last decade, non-invasive methods such as liquid biopsy have increasingly replaced invasive techniques for diagnosing and monitoring diseases. Liquid biopsies are easier to obtain, highly sensitive, cost-effective per sample, and can be used for real-time monitoring, such as tracking drug response. To uncover molecular and cellular characteristics today, blood, saliva, urine, or cerebrospinal fluid are typically analyzed. In this methodological proof-of-concept study, we propose that patient profiling can be facilitated by assessing surface markers on extracellular vesicles (EVs) directly in plasma without prior purification. EV composition reflects the physiological or pathological state of their parent cell, making EVs valuable tools for biomarker discovery and understanding disease mechanisms. Plasma and purified EVs from 30 ischemic stroke patients were analyzed for 17 surface markers using an in-house protein microarray method (EV Array). The findings indicate that measurements on EVs directly in plasma and on purified EVs show similar patterns in expression of surface markers, supporting the feasibility of omitting purification in EV profiling. This knowledge can provide faster monitoring of various diseases, prevent delays in patient profiling, and optimize patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.